uniQure N.V. — Company profile
Healthcare · Biotechnology · Netherlands
Last price 24.83 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.72B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Details
| Name | uniQure N.V. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 221 |
| Founded | 1998 |
| Ipo Date | 2007-06-20 |
| Ceo | Matthew Kapusta |
| Country | Netherlands |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | NL0010696654 |
| Cusip | N90064101 |
| Cik | 0001590560 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Matthew Craig Kapusta CPA | Chief Executive Officer and Executive Director |
| Christian Klemt | Chief Financial Officer, Principal Financial Officer and GM of Amsterdam Site |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal and Compliance Officer and Corporate Secretary |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations Officer |
| Richard Porter Ph.D. | Chief Business and Scientific Officer |
| Chiara Elizabeth Russo | Senior Director of Investor Relations |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director |
| Erin Boyer | Chief People and Culture Officer |
Contact
| Address | Paasheuvelweg 25, Amsterdam, 1105 BP, Netherlands |
| Phone | 31 20 240 6000 |
| Website | https://www.uniqure.com |